HK1009089A1 - Composition for sustained release of human growth hormone - Google Patents
Composition for sustained release of human growth hormoneInfo
- Publication number
- HK1009089A1 HK1009089A1 HK98110029A HK98110029A HK1009089A1 HK 1009089 A1 HK1009089 A1 HK 1009089A1 HK 98110029 A HK98110029 A HK 98110029A HK 98110029 A HK98110029 A HK 98110029A HK 1009089 A1 HK1009089 A1 HK 1009089A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- composition
- sustained release
- hgh
- biologically active
- polymer
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 9
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 9
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 9
- 238000013268 sustained release Methods 0.000 title abstract 7
- 239000012730 sustained-release form Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 abstract 6
- 239000002245 particle Substances 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 4
- 229920000249 biocompatible polymer Polymers 0.000 abstract 3
- 230000036765 blood level Effects 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/473,544 US5654010A (en) | 1992-12-02 | 1995-06-07 | Composition for sustained release of human growth hormone |
US08/477,725 US5667808A (en) | 1992-12-02 | 1995-06-07 | Composition for sustained release of human growth hormone |
PCT/US1996/008086 WO1996040072A2 (en) | 1995-06-07 | 1996-06-03 | Composition for sustained release of human growth hormone |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1009089A1 true HK1009089A1 (en) | 1999-09-10 |
Family
ID=27044171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK98110029A HK1009089A1 (en) | 1995-06-07 | 1998-08-19 | Composition for sustained release of human growth hormone |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0831787B1 (xx) |
JP (1) | JPH11506740A (xx) |
CN (1) | CN1102854C (xx) |
AT (1) | ATE204468T1 (xx) |
AU (1) | AU708756B2 (xx) |
BR (1) | BR9608542A (xx) |
CA (1) | CA2223436A1 (xx) |
CZ (1) | CZ288147B6 (xx) |
DE (1) | DE69614685T2 (xx) |
DK (1) | DK0831787T3 (xx) |
ES (1) | ES2161366T3 (xx) |
HK (1) | HK1009089A1 (xx) |
HU (1) | HUP9900870A3 (xx) |
IL (1) | IL122385A (xx) |
MX (1) | MX9709698A (xx) |
NO (1) | NO316104B1 (xx) |
NZ (1) | NZ310644A (xx) |
PL (1) | PL184531B1 (xx) |
PT (1) | PT831787E (xx) |
RU (1) | RU2161502C2 (xx) |
SK (1) | SK281571B6 (xx) |
WO (1) | WO1996040072A2 (xx) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0835101B1 (en) * | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
NZ508878A (en) | 1998-05-15 | 2003-08-29 | Genentech Inc | IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
EP1978029A3 (en) | 1999-06-15 | 2008-10-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
EP1661997A1 (en) | 1999-12-01 | 2006-05-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1897946B1 (en) | 1999-12-23 | 2012-07-11 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
CA2397207C (en) | 2000-01-13 | 2013-12-03 | Genentech, Inc. | Novel stra6 polypeptides |
US6740520B2 (en) | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
EP1265630B1 (en) | 2000-03-24 | 2006-06-07 | Genentech, Inc. | Use of insulin for the treatment of cartilagenous disorders |
US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP2014298A3 (en) | 2000-08-24 | 2009-10-07 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US8637077B2 (en) | 2000-12-28 | 2014-01-28 | Takeda Pharmaceutical Company Limited | Sustained-release preparation |
US7271150B2 (en) | 2001-05-14 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
WO2003000282A1 (en) | 2001-06-21 | 2003-01-03 | Genentech, Inc. | Sustained release formulation |
US7303896B2 (en) | 2002-02-25 | 2007-12-04 | Genentech, Inc. | Nucleic acid encoding novel type-1 cytokine receptor GLM-R |
LT2335725T (lt) | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
PL1636593T3 (pl) | 2003-06-06 | 2009-08-31 | Genentech Inc | Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met. |
ES2751414T5 (es) | 2003-07-08 | 2024-04-23 | Novartis Pharma Ag | Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F |
AU2004298483A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
EP2075254A1 (en) | 2004-03-30 | 2009-07-01 | NsGene A/S | Therapeutic use of a growth factor, NsG33 |
KR101150242B1 (ko) | 2004-10-27 | 2012-06-13 | 유니버시티 오브 덴버 | 부신피질 자극 호르몬 유사체 및 관련 방법 |
US20060275230A1 (en) | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
CA2590136A1 (en) | 2004-12-10 | 2006-06-15 | Talima Therapeutics, Inc. | Compositions and methods for treating conditions of the nail unit |
US7858843B2 (en) | 2005-06-06 | 2010-12-28 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US8389469B2 (en) | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
ES2569917T3 (es) | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
US7582291B2 (en) | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
DE602006018746D1 (de) | 2005-08-24 | 2011-01-20 | Univ Rockefeller | Ply-gbs-lysinmutanten |
EP1962584A2 (en) | 2005-11-21 | 2008-09-03 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
NZ568809A (en) | 2005-12-22 | 2011-08-26 | Genentech Inc | Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents |
AU2007233263A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
SG170728A1 (en) | 2006-03-23 | 2011-05-30 | Novartis Ag | Anti-tumor cell antigen antibody therapeutics |
CN101467039B (zh) | 2006-04-10 | 2013-11-06 | 健泰科生物技术公司 | 散乱蛋白pdz调节剂 |
CA2649387A1 (en) | 2006-04-19 | 2008-03-27 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
CA2661521C (en) * | 2006-08-31 | 2016-04-12 | Novartis Ag | Pharmaceutical compositions comprising hgh for oral delivery |
US7695718B2 (en) | 2006-12-20 | 2010-04-13 | Xoma Technology Ltd. | Methods for the treatment of IL-1β related diseases |
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
KR20100058541A (ko) * | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법 |
CA2710252C (en) | 2007-12-20 | 2017-03-28 | Xoma Technology Ltd. | Methods for the treatment of gout |
GB0812742D0 (en) | 2008-07-11 | 2008-08-20 | Critical Pharmaceuticals Ltd | Process |
US8535912B2 (en) | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
BR112012017535A2 (pt) | 2010-01-15 | 2019-09-24 | Of Medicine And Dentistry Of New Jersey University | uso de compostos de vanádio para cicatrização de osso |
ES2722201T3 (es) | 2010-03-22 | 2019-08-08 | Hoffmann La Roche | Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas |
BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
MY184736A (en) | 2010-06-24 | 2021-04-20 | Genentech Inc | Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations |
CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
EP2621512B1 (en) | 2010-10-01 | 2016-04-06 | NsGene A/S | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
JP6080763B2 (ja) | 2010-10-08 | 2017-02-15 | シャンハイ クーシン バイオテック カンパニー,リミテッド | モエシンモジュレーターおよびその使用 |
EP2624852B1 (en) | 2010-10-08 | 2016-12-14 | Shanghai Kexin Biotech Co., Ltd | Diagnostic and therapeutic uses of moesin fragments |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
CN102875683B (zh) * | 2011-07-11 | 2014-06-11 | 旭华(上海)生物研发中心有限公司 | 长效重组人生长激素的Fc融合蛋白 |
FI3091029T3 (fi) | 2011-10-31 | 2023-03-20 | Hoffmann La Roche | Anti-il13-vasta-aineformulaatioita |
WO2013096516A1 (en) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Methods for treating acne |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
US9498612B2 (en) | 2013-03-14 | 2016-11-22 | Hallux, Inc. | Method of treating infections, diseases or disorders of nail unit |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
EP3022221B1 (en) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Humanized antibodies with ultralong complementarity determining regions |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
US10286078B2 (en) | 2013-09-13 | 2019-05-14 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
ES2741308T3 (es) | 2013-10-15 | 2020-02-10 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos |
EP3057994B1 (en) | 2013-10-15 | 2020-09-23 | The Scripps Research Institute | Peptidic chimeric antigen receptor t cell switches and uses thereof |
CN104623639A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | 白介素22二聚体在制备治疗胰腺炎药物中的应用 |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
CN106456589B (zh) | 2013-12-18 | 2020-07-07 | 斯克利普斯研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
NL2014230B1 (en) | 2015-02-04 | 2016-10-12 | Stichting Vu-Vumc | Wound healing formulation. |
MA41629A (fr) | 2015-03-04 | 2018-01-09 | Center For Human Reproduction | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité |
US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
EP3310376A4 (en) | 2015-06-17 | 2019-01-23 | The California Institute for Biomedical Research | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF |
WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
EP3529268A1 (en) | 2016-10-19 | 2019-08-28 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
MX2021012032A (es) | 2019-04-01 | 2021-11-03 | Genentech Inc | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. |
US20210047425A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
JP2022554187A (ja) | 2019-10-24 | 2022-12-28 | ミノトール セラピューティクス インコーポレイテッド | キメラサイトカイン改変抗体およびその使用方法 |
CA3217865A1 (en) | 2021-04-28 | 2022-11-03 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
CN117940149A (zh) | 2021-05-06 | 2024-04-26 | 霍巴治疗公司 | 化疗诱导的神经性疼痛的预防和治疗 |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
ES2151541T3 (es) * | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
BR9509201A (pt) * | 1994-09-09 | 1997-12-30 | Takeda Chemical Industries Ltd | Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada |
-
1996
- 1996-06-03 PT PT96919016T patent/PT831787E/pt unknown
- 1996-06-03 EP EP96919016A patent/EP0831787B1/en not_active Expired - Lifetime
- 1996-06-03 RU RU97119935/14A patent/RU2161502C2/ru not_active IP Right Cessation
- 1996-06-03 SK SK1671-97A patent/SK281571B6/sk unknown
- 1996-06-03 BR BR9608542-8A patent/BR9608542A/pt not_active Application Discontinuation
- 1996-06-03 DK DK96919016T patent/DK0831787T3/da active
- 1996-06-03 WO PCT/US1996/008086 patent/WO1996040072A2/en not_active Application Discontinuation
- 1996-06-03 ES ES96919016T patent/ES2161366T3/es not_active Expired - Lifetime
- 1996-06-03 DE DE69614685T patent/DE69614685T2/de not_active Expired - Fee Related
- 1996-06-03 IL IL12238596A patent/IL122385A/xx not_active IP Right Cessation
- 1996-06-03 HU HU9900870A patent/HUP9900870A3/hu unknown
- 1996-06-03 AU AU61469/96A patent/AU708756B2/en not_active Ceased
- 1996-06-03 CN CN96194614A patent/CN1102854C/zh not_active Expired - Fee Related
- 1996-06-03 NZ NZ310644A patent/NZ310644A/xx unknown
- 1996-06-03 CZ CZ19973907A patent/CZ288147B6/cs not_active IP Right Cessation
- 1996-06-03 CA CA002223436A patent/CA2223436A1/en not_active Abandoned
- 1996-06-03 JP JP9500870A patent/JPH11506740A/ja active Pending
- 1996-06-03 PL PL96323832A patent/PL184531B1/pl not_active IP Right Cessation
- 1996-06-03 AT AT96919016T patent/ATE204468T1/de not_active IP Right Cessation
-
1997
- 1997-12-05 NO NO19975708A patent/NO316104B1/no unknown
- 1997-12-05 MX MX9709698A patent/MX9709698A/es not_active IP Right Cessation
-
1998
- 1998-08-19 HK HK98110029A patent/HK1009089A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69614685T2 (de) | 2002-06-27 |
CN1187120A (zh) | 1998-07-08 |
PL323832A1 (en) | 1998-04-27 |
DK0831787T3 (da) | 2001-12-17 |
JPH11506740A (ja) | 1999-06-15 |
ATE204468T1 (de) | 2001-09-15 |
CZ390797A3 (cs) | 1998-07-15 |
NO975708D0 (no) | 1997-12-05 |
NO975708L (no) | 1998-02-05 |
PL184531B1 (pl) | 2002-11-29 |
NZ310644A (en) | 1999-08-30 |
CN1102854C (zh) | 2003-03-12 |
MX9709698A (es) | 1998-07-31 |
WO1996040072A3 (en) | 1997-01-23 |
HUP9900870A3 (en) | 2001-04-28 |
CZ288147B6 (en) | 2001-05-16 |
PT831787E (pt) | 2002-02-28 |
IL122385A0 (en) | 1998-06-15 |
BR9608542A (pt) | 1999-11-30 |
AU708756B2 (en) | 1999-08-12 |
NO316104B1 (no) | 2003-12-15 |
CA2223436A1 (en) | 1996-12-19 |
WO1996040072A2 (en) | 1996-12-19 |
EP0831787A2 (en) | 1998-04-01 |
SK281571B6 (sk) | 2001-05-10 |
IL122385A (en) | 2001-01-11 |
DE69614685D1 (de) | 2001-09-27 |
RU2161502C2 (ru) | 2001-01-10 |
ES2161366T3 (es) | 2001-12-01 |
HUP9900870A2 (hu) | 1999-09-28 |
SK167197A3 (en) | 1998-06-03 |
AU6146996A (en) | 1996-12-30 |
EP0831787B1 (en) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL122385A (en) | Composition for sustained release of human growth hormone | |
MX9709699A (es) | Composicion para la liberacion sostenida de eritropoyetina no agregada. | |
WO2001043749A3 (en) | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration | |
EP1570823A3 (en) | Substained analgesia achieved with buprenorphine | |
ATE228832T1 (de) | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung | |
CA2474698A1 (en) | Polymer-based compositions for sustained release | |
AU5962496A (en) | Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents | |
US5972384A (en) | Use of biologically active glass as a drug delivery system | |
JPH07187994A (ja) | 薬物放出制御製剤 | |
EP1011637A4 (en) | MODULATION OF DRUG LOAD IN MULTIFICULAR LIPOSOMES | |
AU7004194A (en) | Drug system | |
US5342622A (en) | Subdermal biocompatible implants | |
SK281461B6 (sk) | Kolagénový prípravok na riadené uvoľňovanie účinných látok | |
AU5673399A (en) | Compositions and methods for treating intracellular infections | |
WO2020166820A1 (ko) | 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물 | |
EP0050650A1 (en) | Prolonged action drug formulation | |
JPH0513130B2 (xx) | ||
JPH06507634A (ja) | 局所炎症反応の放出制御型薬物送達手段としての設計 | |
Lim | Development of Local Drug Delivery System: Prolonged Sciatic Nerve Blockade From Biodegradable Microspheres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20080603 |